MedPath

Mabscale, LLC

🇷🇺Russia
Ownership
Private
Employees
-
Market Cap
-
Website
http://mabscale.ru/

Clinical Trials

4

Active:2
Completed:0

Trial Phases

2 Phases

Phase 1:2
Phase 3:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Phase 1
2 (50.0%)
Phase 3
2 (50.0%)

Study, Evaluating Pharmacokinetics, Pharmacodynamics, Immunogenicity and Safety Profiles of Rituximab Compared to MabThera® in Patients With Rheumatoid Arthritis

Phase 1
Active, not recruiting
Conditions
Rheumatoid Arthritis
Interventions
First Posted Date
2023-12-18
Last Posted Date
2024-06-06
Lead Sponsor
Mabscale, LLC
Target Recruit Count
208
Registration Number
NCT06175338
Locations
🇷🇺

Immanuel Kant Baltic Federal University, Kaliningrad, Russian Federation

🇷🇺

Scientific-Research Medical Complex Your Health, Kazan, Russian Federation

🇷🇺

LLC "Medical Center Revma-Med", Kemerovo, Russian Federation

and more 9 locations

Study Evaluation of the Efficacy, Safety and Immunogenicity of Adalimumab in Comparison With Humira®

Phase 3
Recruiting
Conditions
Plaque Psoriasis
Interventions
First Posted Date
2023-08-22
Last Posted Date
2023-11-29
Lead Sponsor
Mabscale, LLC
Target Recruit Count
494
Registration Number
NCT06005532
Locations
🇷🇺

Regional dermatovenerologic dispensary, Barnaul, Russian Federation

🇷🇺

Chelyabinsk Regional Clinical Dermatovenerologic Dispensary, Chelyabinsk, Russian Federation

🇷🇺

Interregional Clinical Diagnostic Center, Kazan', Russian Federation

and more 6 locations

Study, Evaluating Pharmacokinetics, Immunogenicity and Safety Profiles of Pertuzumab Compared to Perjeta® in Healthy Man

Phase 1
Active, not recruiting
Conditions
Healthy Men
Interventions
First Posted Date
2023-04-24
Last Posted Date
2024-08-16
Lead Sponsor
Mabscale, LLC
Target Recruit Count
114
Registration Number
NCT05825781
Locations
🇷🇺

Central Clinical Hospital "RZD-Medicina", Moscow, Russian Federation

A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer

Phase 3
Recruiting
Conditions
Non-Small Cell Lung Cancer
Interventions
First Posted Date
2022-12-16
Last Posted Date
2024-08-16
Lead Sponsor
Mabscale, LLC
Target Recruit Count
620
Registration Number
NCT05654454
Locations
🇷🇺

Arkhangelsk Clinical Oncological Dispensary, Arkhangel'sk, Russian Federation

🇷🇺

State Budget Healthcare Institution Ivanovo Regional Oncology Dispensary, Ivanovo, Russian Federation

🇷🇺

Kaluga Regional Clinical Oncology Dispensary, Kaluga, Russian Federation

and more 25 locations

News

No news found
© Copyright 2025. All Rights Reserved by MedPath